You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePentobarbital
Accession NumberDB00312  (APRD01174)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
Structure
Thumb
Synonyms
5-Ethyl-5-(1-methyl-butyl)-pyrimidine-2,4,6-trione
5-Ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
5-ethyl-5-(1-methylbutyl)barbituric acid
5-ethyl-5-(sec-pentyl)barbituric acid
Nembutal
Pentobarbital
Pentobarbitone
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nembutal Sodium Cap 100mgCapsule100 mgOralAbbott Laboratories, Limited1951-12-311997-08-18Canada
Nembutal Sodium Inj 50mg/mlSolution50 mgIntramuscular; IntravenousAbbott Laboratories, Limited1976-12-312008-06-06Canada
Nova Rectal Sup 25mgSuppository25 mgRectalSabex Inc1984-12-311999-08-12Canada
Nova Rectal Sup 50mgSuppository50 mgRectalSabex Inc1984-12-312001-08-02Canada
Novo-pentobarb 100mgCapsule100 mgOralNovopharm Limited1967-12-312005-08-10Canada
Pentobarbital Sodium Cap 50mgCapsule50 mgOralSands Pharm1972-12-311996-09-10Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nembutal SodiumInjection50 mg/mLIntramuscular; IntravenousOak Pharmaceuticals, Inc. (Subsidiary of Akorn, Inc.)1973-09-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
NembutalLundbeck
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Pentobarbital Sodium
Thumb
  • InChI Key: QGMRQYFBGABWDR-UHFFFAOYNA-M
  • Monoisotopic Mass: 248.113687095
  • Average Mass: 248.254
DBSALT000442
Categories
UNIII4744080IR
CAS number76-74-4
WeightAverage: 226.2722
Monoisotopic: 226.131742452
Chemical FormulaC11H18N2O3
InChI KeyWEXRUCMBJFQVBZ-UHFFFAOYSA-N
InChI
InChI=1S/C11H18N2O3/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
IUPAC Name
5-ethyl-5-(pentan-2-yl)-1,3-diazinane-2,4,6-trione
SMILES
CCCC(C)C1(CC)C(=O)NC(=O)NC1=O
Pharmacology
IndicationFor the short-term treatment of insomnia.
Structured Indications
PharmacodynamicsPentobarbital, a barbiturate, is used for the treatment of short term insomnia. It belongs to a group of medicines called central nervous system (CNS) depressants that induce drowsiness and relieve tension or nervousness. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.
Mechanism of actionPentobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. All of these effects are associated with marked decreases in GABA-sensitive neuronal calcium conductance (gCa). The net result of barbiturate action is acute potentiation of inhibitory GABAergic tone. Barbiturates also act through potent (if less well characterized) and direct inhibition of excitatory AMPA-type glutamate receptors, resulting in a profound suppression of glutamatergic neurotransmission.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
potentiator
HumanP14867 details
Gamma-aminobutyric acid receptor subunit alpha-2Proteinyes
potentiator
HumanP47869 details
Gamma-aminobutyric acid receptor subunit alpha-3Proteinyes
potentiator
HumanP34903 details
Gamma-aminobutyric acid receptor subunit alpha-4Proteinyes
potentiator
HumanP48169 details
Gamma-aminobutyric acid receptor subunit alpha-5Proteinyes
potentiator
HumanP31644 details
Gamma-aminobutyric acid receptor subunit alpha-6Proteinyes
potentiator
HumanQ16445 details
Neuronal acetylcholine receptor subunit alpha-4Proteinunknown
antagonist
HumanP43681 details
Neuronal acetylcholine receptor subunit alpha-7Proteinunknown
antagonist
HumanP36544 details
Glutamate receptor 2Proteinunknown
antagonist
HumanP42262 details
Glutamate receptor ionotropic, kainate 2Proteinunknown
antagonist
HumanQ13002 details
GABA-A receptor (anion channel)Protein groupyes
positive allosteric modulator
Humannot applicabledetails
NMDA receptorProtein groupunknown
antagonist
Humannot applicabledetails
Related Articles
AbsorptionBarbiturates are absorbed in varying degrees following oral, rectal, or parenteral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

by hepatic microsomal enzyme system

Route of eliminationBarbiturates are metabolized primarily by the hepatic microsomal enzyme system, and the metabolic products are excreted in the urine, and less commonly, in the feces. Approximately 25 to 50 percent of a dose of aprobarbital or phenobarbital is eliminated unchanged in the urine, whereas the amount of other barbiturates excreted unchanged in the urine is negligible.
Half life5 to 50 hours (dose dependent)
ClearanceNot Available
ToxicitySymptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with 1,1,1,2 Tetrafluoroethane.Investigational
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Pentobarbital.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Pentobarbital.Experimental, Illicit
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be decreased when it is combined with Pentobarbital.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be decreased when it is combined with Pentobarbital.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Pentobarbital is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Pentobarbital.Approved
AcebutololPentobarbital may increase the hypotensive activities of Acebutolol.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Pentobarbital.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Pentobarbital.Approved
AcetazolamidePentobarbital may increase the hypotensive activities of Acetazolamide.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be increased when combined with Pentobarbital.Approved
adipiplonThe risk or severity of adverse effects can be increased when Pentobarbital is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Agomelatine.Approved, Investigational
AlbendazoleThe metabolism of Albendazole can be increased when combined with Pentobarbital.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be increased when combined with Pentobarbital.Approved
AldesleukinPentobarbital may increase the hypotensive activities of Aldesleukin.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Pentobarbital.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Alfaxalone.Vet Approved
AlfentanilThe metabolism of Alfentanil can be increased when combined with Pentobarbital.Approved, Illicit
AlfuzosinThe metabolism of Alfuzosin can be increased when combined with Pentobarbital.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be increased when combined with Pentobarbital.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be increased when combined with Pentobarbital.Approved
AlmotriptanThe metabolism of Almotriptan can be increased when combined with Pentobarbital.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be increased when combined with Pentobarbital.Approved
AlosetronThe metabolism of Alosetron can be increased when combined with Pentobarbital.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe metabolism of Alprazolam can be increased when combined with Pentobarbital.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Pentobarbital.Approved, Withdrawn
AmbrisentanThe metabolism of Ambrisentan can be increased when combined with Pentobarbital.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be increased when combined with Pentobarbital.Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Pentobarbital.Experimental
AmcinonideThe serum concentration of Amcinonide can be decreased when it is combined with Pentobarbital.Approved
AmifostinePentobarbital may increase the hypotensive activities of Amifostine.Approved, Investigational
AmiloridePentobarbital may increase the hypotensive activities of Amiloride.Approved
AmineptineThe metabolism of Amineptine can be increased when combined with Pentobarbital.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be increased when combined with Pentobarbital.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be increased when combined with Pentobarbital.Approved
AmiodaroneThe metabolism of Amiodarone can be increased when combined with Pentobarbital.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Amisulpride.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be increased when combined with Pentobarbital.Approved
AmlodipineThe metabolism of Amlodipine can be increased when combined with Pentobarbital.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Amperozide.Experimental
Amphotericin BPentobarbital may increase the hypotensive activities of Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be increased when combined with Pentobarbital.Approved
AmrinoneThe metabolism of Amrinone can be increased when combined with Pentobarbital.Approved
Amyl NitritePentobarbital may increase the hypotensive activities of Amyl Nitrite.Approved
AnecortaveThe serum concentration of Anecortave can be decreased when it is combined with Pentobarbital.Investigational
AntipyrineThe metabolism of Antipyrine can be increased when combined with Pentobarbital.Approved
Aop200704The serum concentration of Aop200704 can be decreased when it is combined with Pentobarbital.Investigational
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Pentobarbital.Approved
ApomorphinePentobarbital may increase the hypotensive activities of Apomorphine.Approved, Investigational
ApraclonidinePentobarbital may increase the hypotensive activities of Apraclonidine.Approved
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Pentobarbital.Approved, Investigational
AprepitantThe metabolism of Aprepitant can be increased when combined with Pentobarbital.Approved, Investigational
ArformoterolThe metabolism of Arformoterol can be increased when combined with Pentobarbital.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be increased when combined with Pentobarbital.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Pentobarbital.Approved, Investigational
ArmodafinilThe metabolism of Pentobarbital can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Pentobarbital.Approved
Arsenic trioxidePentobarbital may increase the hypotensive activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Pentobarbital resulting in a loss in efficacy.Approved
ArticaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Articaine.Approved
AsenapineThe metabolism of Asenapine can be increased when combined with Pentobarbital.Approved
AstemizoleThe metabolism of Astemizole can be increased when combined with Pentobarbital.Approved, Withdrawn
AtazanavirThe metabolism of Atazanavir can be increased when combined with Pentobarbital.Approved, Investigational
AtenololPentobarbital may increase the hypotensive activities of Atenolol.Approved
AtorvastatinThe metabolism of Atorvastatin can be increased when combined with Pentobarbital.Approved
AvanafilThe metabolism of Avanafil can be increased when combined with Pentobarbital.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Pentobarbital.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Azaperone.Vet Approved
AzelastinePentobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe metabolism of Azelastine can be increased when combined with Pentobarbital.Approved
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Pentobarbital.Approved
Azilsartan medoxomilPentobarbital may increase the hypotensive activities of Azilsartan medoxomil.Approved
AzimilideThe metabolism of Azimilide can be increased when combined with Pentobarbital.Investigational
AzithromycinThe metabolism of Azithromycin can be increased when combined with Pentobarbital.Approved
BaclofenThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Baclofen.Approved
BanoxantroneThe metabolism of Banoxantrone can be increased when combined with Pentobarbital.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Barbital.Illicit
BarnidipineThe metabolism of Barnidipine can be increased when combined with Pentobarbital.Approved
BeclomethasoneThe serum concentration of Beclomethasone can be decreased when it is combined with Pentobarbital.Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Pentobarbital.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Pentobarbital.Approved
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Pentobarbital.Experimental
BenazeprilPentobarbital may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazidePentobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved
BenidipineThe metabolism of Benidipine can be increased when combined with Pentobarbital.Approved
BenperidolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Benzocaine.Approved
BenzphetamineThe metabolism of Benzphetamine can be increased when combined with Pentobarbital.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be increased when combined with Pentobarbital.Approved
BepridilThe metabolism of Bepridil can be increased when combined with Pentobarbital.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
BetaxololPentobarbital may increase the hypotensive activities of Betaxolol.Approved
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Pentobarbital.Approved
BexaroteneThe metabolism of Bexarotene can be increased when combined with Pentobarbital.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be increased when combined with Pentobarbital.Approved
BicalutamideThe metabolism of Bicalutamide can be increased when combined with Pentobarbital.Approved
BisoprololThe metabolism of Bisoprolol can be increased when combined with Pentobarbital.Approved
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Pentobarbital.Approved
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Pentobarbital.Approved
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Pentobarbital.Approved, Investigational
BosentanThe metabolism of Bosentan can be increased when combined with Pentobarbital.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Pentobarbital.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Pentobarbital.Approved
BretyliumPentobarbital may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Pentobarbital.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved
BrinzolamideThe metabolism of Brinzolamide can be increased when combined with Pentobarbital.Approved
BromazepamThe metabolism of Bromazepam can be increased when combined with Pentobarbital.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be increased when combined with Pentobarbital.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be increased when combined with Pentobarbital.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Brotizolam.Approved, Withdrawn
BucindololThe serum concentration of Bucindolol can be decreased when it is combined with Pentobarbital.Investigational
BudesonideThe metabolism of Budesonide can be increased when combined with Pentobarbital.Approved
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Pentobarbital.Experimental, Investigational
BumetanidePentobarbital may increase the hypotensive activities of Bumetanide.Approved
BupivacaineThe metabolism of Bupivacaine can be increased when combined with Pentobarbital.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Pentobarbital.Approved
BuprenorphinePentobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be increased when combined with Pentobarbital.Approved
BuspironeThe metabolism of Buspirone can be increased when combined with Pentobarbital.Approved, Investigational
BusulfanThe metabolism of Busulfan can be increased when combined with Pentobarbital.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pentobarbital.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Butorphanol.Approved, Illicit, Vet Approved
CabazitaxelThe metabolism of Cabazitaxel can be increased when combined with Pentobarbital.Approved
CabergolineThe metabolism of Cabergoline can be increased when combined with Pentobarbital.Approved
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Pentobarbital.Approved
CaffeineThe metabolism of Caffeine can be increased when combined with Pentobarbital.Approved
CaiThe metabolism of Cai can be increased when combined with Pentobarbital.Investigational
CalcitriolThe metabolism of Calcitriol can be increased when combined with Pentobarbital.Approved, Nutraceutical
CanagliflozinThe metabolism of Canagliflozin can be increased when combined with Pentobarbital.Approved
CandesartanPentobarbital may increase the hypotensive activities of Candesartan.Approved
CannabidiolThe serum concentration of Cannabidiol can be decreased when it is combined with Pentobarbital.Approved, Investigational
CaptoprilPentobarbital may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Carbamazepine can be increased when combined with Pentobarbital.Approved, Investigational
CarbetocinPentobarbital may increase the hypotensive activities of Carbetocin.Approved
CarbinoxamineThe metabolism of Carbinoxamine can be increased when combined with Pentobarbital.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Carfentanil.Illicit, Vet Approved
CariprazineThe metabolism of Cariprazine can be increased when combined with Pentobarbital.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Carisoprodol.Approved
CarteololPentobarbital may increase the hypotensive activities of Carteolol.Approved
CarvedilolThe metabolism of Carvedilol can be increased when combined with Pentobarbital.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be increased when combined with Pentobarbital.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be increased when combined with Pentobarbital.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be increased when combined with Pentobarbital.Approved, Vet Approved
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Pentobarbital.Approved
CerivastatinThe metabolism of Cerivastatin can be increased when combined with Pentobarbital.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Cetirizine.Approved
CevimelineThe metabolism of Cevimeline can be increased when combined with Pentobarbital.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be increased when combined with Pentobarbital.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Pentobarbital can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be increased when combined with Pentobarbital.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Chloroquine can be increased when combined with Pentobarbital.Approved, Vet Approved
ChlorothiazidePentobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe therapeutic efficacy of Chlorotrianisene can be decreased when used in combination with Pentobarbital.Withdrawn
ChlorphenamineThe metabolism of Chlorphenamine can be increased when combined with Pentobarbital.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be increased when combined with Pentobarbital.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidonePentobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be increased when combined with Pentobarbital.Approved
CholecalciferolThe metabolism of Cholecalciferol can be increased when combined with Pentobarbital.Approved, Nutraceutical
CiclesonideThe metabolism of Ciclesonide can be increased when combined with Pentobarbital.Approved, Investigational
CilazaprilPentobarbital may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe metabolism of Cilnidipine can be increased when combined with Pentobarbital.Approved
CilostazolThe metabolism of Cilostazol can be increased when combined with Pentobarbital.Approved
CimetidineThe metabolism of Pentobarbital can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Cinacalcet can be increased when combined with Pentobarbital.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Pentobarbital.Approved
CisaprideThe metabolism of Cisapride can be increased when combined with Pentobarbital.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Citalopram can be increased when combined with Pentobarbital.Approved
ClarithromycinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Pentobarbital.Approved
ClemastineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Clemastine.Approved
ClevidipinePentobarbital may increase the hypotensive activities of Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Clidinium.Approved
ClindamycinThe metabolism of Clindamycin can be increased when combined with Pentobarbital.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be increased when combined with Pentobarbital.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be decreased when it is combined with Pentobarbital.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be decreased when it is combined with Pentobarbital.Approved
ClocortoloneThe serum concentration of Clocortolone can be decreased when it is combined with Pentobarbital.Approved
ClofarabinePentobarbital may increase the hypotensive activities of Clofarabine.Approved, Investigational
ClofazimineThe metabolism of Clofazimine can be increased when combined with Pentobarbital.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be increased when combined with Pentobarbital.Approved
clomethiazoleThe metabolism of clomethiazole can be increased when combined with Pentobarbital.Investigational
ClomipramineThe metabolism of Clomipramine can be increased when combined with Pentobarbital.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be increased when combined with Pentobarbital.Approved, Illicit
ClonidineThe metabolism of Clonidine can be increased when combined with Pentobarbital.Approved
ClopidogrelThe metabolism of Clopidogrel can be increased when combined with Pentobarbital.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be increased when combined with Pentobarbital.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be increased when combined with Pentobarbital.Approved, Illicit
ClotrimazoleThe metabolism of Pentobarbital can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Pentobarbital.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Pentobarbital.Approved
CocaineThe metabolism of Cocaine can be increased when combined with Pentobarbital.Approved, Illicit
CodeineThe metabolism of Codeine can be increased when combined with Pentobarbital.Approved, Illicit
ColchicineThe metabolism of Colchicine can be increased when combined with Pentobarbital.Approved
ConivaptanThe metabolism of Conivaptan can be increased when combined with Pentobarbital.Approved, Investigational
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be increased when combined with Pentobarbital.Approved
Cortisone acetateThe metabolism of Cortisone acetate can be increased when combined with Pentobarbital.Approved
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Pentobarbital.Approved
CyclizineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be increased when combined with Pentobarbital.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be increased when combined with Pentobarbital.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Cyproheptadine.Approved
CytarabineThe metabolism of Cytarabine can be increased when combined with Pentobarbital.Approved, Investigational
DabrafenibThe serum concentration of Pentobarbital can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Pentobarbital.Approved
DantroleneThe metabolism of Dantrolene can be increased when combined with Pentobarbital.Approved
DapagliflozinThe metabolism of Dapagliflozin can be increased when combined with Pentobarbital.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pentobarbital.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dapoxetine.Investigational
DapsoneThe metabolism of Dapsone can be increased when combined with Pentobarbital.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be increased when combined with Pentobarbital.Approved, Investigational
DarodipineThe metabolism of Darodipine can be increased when combined with Pentobarbital.Experimental
DarunavirThe metabolism of Darunavir can be increased when combined with Pentobarbital.Approved
DasabuvirThe metabolism of Dasabuvir can be increased when combined with Pentobarbital.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Pentobarbital.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be increased when combined with Pentobarbital.Approved
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Pentobarbital.Investigational
DelavirdineThe metabolism of Delavirdine can be increased when combined with Pentobarbital.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Desflurane.Approved
DesipramineThe metabolism of Desipramine can be increased when combined with Pentobarbital.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Desloratadine.Approved, Investigational
DesogestrelThe therapeutic efficacy of Desogestrel can be decreased when used in combination with Pentobarbital.Approved
DesoximetasoneThe serum concentration of Desoximetasone can be decreased when it is combined with Pentobarbital.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be decreased when it is combined with Pentobarbital.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Pentobarbital.Experimental, Vet Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be increased when combined with Pentobarbital.Approved
DetomidineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
DexamethasoneThe metabolism of Dexamethasone can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be decreased when it is combined with Pentobarbital.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be increased when combined with Pentobarbital.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe metabolism of Dextropropoxyphene can be increased when combined with Pentobarbital.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dezocine.Approved
DiazepamThe metabolism of Diazepam can be increased when combined with Pentobarbital.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be increased when combined with Pentobarbital.Approved, Vet Approved
DiclofenamidePentobarbital may increase the hypotensive activities of Diclofenamide.Approved
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Pentobarbital.Approved
DienestrolThe therapeutic efficacy of Dienestrol can be decreased when used in combination with Pentobarbital.Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Pentobarbital.Approved
DiethylstilbestrolThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Pentobarbital.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Difenoxin.Approved, Illicit
DiflorasoneThe serum concentration of Diflorasone can be decreased when it is combined with Pentobarbital.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be decreased when it is combined with Pentobarbital.Approved
DifluprednateThe serum concentration of Difluprednate can be decreased when it is combined with Pentobarbital.Approved
DigitoxinThe metabolism of Digitoxin can be increased when combined with Pentobarbital.Approved
DigoxinThe metabolism of Digoxin can be increased when combined with Pentobarbital.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be increased when combined with Pentobarbital.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be increased when combined with Pentobarbital.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Diltiazem can be increased when combined with Pentobarbital.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dimenhydrinate.Approved
DinutuximabPentobarbital may increase the hypotensive activities of Dinutuximab.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Diphenoxylate.Approved, Illicit
DipyridamolePentobarbital may increase the hypotensive activities of Dipyridamole.Approved
DisopyramideThe metabolism of Disopyramide can be increased when combined with Pentobarbital.Approved
DisulfiramThe metabolism of Disulfiram can be increased when combined with Pentobarbital.Approved
DocetaxelThe metabolism of Docetaxel can be increased when combined with Pentobarbital.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be increased when combined with Pentobarbital.Approved
DolasetronThe metabolism of Dolasetron can be increased when combined with Pentobarbital.Approved
DomperidoneThe metabolism of Domperidone can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be increased when combined with Pentobarbital.Approved
DoramectinThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Doramectin.Vet Approved
DorzolamideThe metabolism of Dorzolamide can be increased when combined with Pentobarbital.Approved
DosulepinThe metabolism of Dosulepin can be increased when combined with Pentobarbital.Approved
DotarizineThe metabolism of Dotarizine can be increased when combined with Pentobarbital.Investigational
DoxazosinPentobarbital may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be increased when combined with Pentobarbital.Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Pentobarbital.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be increased when combined with Pentobarbital.Approved, Investigational
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Pentobarbital is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Pentobarbital.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved, Vet Approved
DrospirenoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Pentobarbital.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Duloxetine.Approved
DutasterideThe metabolism of Dutasteride can be increased when combined with Pentobarbital.Approved, Investigational
DyclonineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dyclonine.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Pentobarbital.Approved
EcgonineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Pentobarbital is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ecopipam.Investigational
EfavirenzThe metabolism of Efavirenz can be increased when combined with Pentobarbital.Approved, Investigational
EfonidipineThe metabolism of Efonidipine can be increased when combined with Pentobarbital.Approved
EletriptanThe metabolism of Eletriptan can be increased when combined with Pentobarbital.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Pentobarbital.Approved
ElvitegravirThe metabolism of Elvitegravir can be increased when combined with Pentobarbital.Approved
EmpagliflozinPentobarbital may increase the hypotensive activities of Empagliflozin.Approved
EnalaprilThe metabolism of Enalapril can be increased when combined with Pentobarbital.Approved, Vet Approved
EnalaprilatPentobarbital may increase the hypotensive activities of Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Pentobarbital.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Pentobarbital.Approved
EperisoneThe metabolism of Eperisone can be increased when combined with Pentobarbital.Approved, Investigational
EpinastineThe metabolism of Epinastine can be increased when combined with Pentobarbital.Approved, Investigational
EplerenoneThe metabolism of Eplerenone can be increased when combined with Pentobarbital.Approved
EpoprostenolPentobarbital may increase the hypotensive activities of Epoprostenol.Approved
EprosartanPentobarbital may increase the hypotensive activities of Eprosartan.Approved
EquileninThe serum concentration of Equilenin can be decreased when it is combined with Pentobarbital.Experimental
EquilinThe serum concentration of Equilin can be decreased when it is combined with Pentobarbital.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be increased when combined with Pentobarbital.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be increased when combined with Pentobarbital.Approved
ErgonovineThe metabolism of Ergonovine can be increased when combined with Pentobarbital.Approved
ErgotamineThe metabolism of Ergotamine can be increased when combined with Pentobarbital.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Pentobarbital.Approved, Investigational
ErythromycinThe metabolism of Erythromycin can be increased when combined with Pentobarbital.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be increased when combined with Pentobarbital.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Pentobarbital can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Pentobarbital.Investigational
EsmololPentobarbital may increase the hypotensive activities of Esmolol.Approved
EsomeprazoleThe metabolism of Esomeprazole can be increased when combined with Pentobarbital.Approved, Investigational
EstazolamThe metabolism of Estazolam can be increased when combined with Pentobarbital.Approved, Illicit
EstradiolThe metabolism of Estradiol can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be increased when combined with Pentobarbital.Approved
EstramustineThe metabolism of Estramustine can be increased when combined with Pentobarbital.Approved
Estrogens, esterifiedThe therapeutic efficacy of Estrogens, esterified can be decreased when used in combination with Pentobarbital.Approved
EstroneThe metabolism of Estrone can be increased when combined with Pentobarbital.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be increased when combined with Pentobarbital.Approved
EszopicloneThe metabolism of Eszopiclone can be increased when combined with Pentobarbital.Approved
Etacrynic acidPentobarbital may increase the hypotensive activities of Etacrynic acid.Approved
EthanolPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pentobarbital.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be increased when combined with Pentobarbital.Approved
EthosuximideThe metabolism of Ethosuximide can be increased when combined with Pentobarbital.Approved
EthotoinThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ethotoin.Approved
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Pentobarbital.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be increased when combined with Pentobarbital.Approved, Illicit
Ethynodiol diacetateThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Pentobarbital.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Pentobarbital.Approved
EtonogestrelThe metabolism of Etonogestrel can be increased when combined with Pentobarbital.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Pentobarbital.Approved
EtoricoxibThe metabolism of Etoricoxib can be increased when combined with Pentobarbital.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Etravirine can be increased when combined with Pentobarbital.Approved
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Pentobarbital.Approved
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Pentobarbital.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ezogabine.Approved
FamciclovirThe metabolism of Famciclovir can be increased when combined with Pentobarbital.Approved
FelbamateThe serum concentration of Pentobarbital can be increased when it is combined with Felbamate.Approved
FelodipineThe metabolism of Felodipine can be increased when combined with Pentobarbital.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe metabolism of Fendiline can be increased when combined with Pentobarbital.Withdrawn
FenofibrateThe metabolism of Fenofibrate can be increased when combined with Pentobarbital.Approved
FenoldopamPentobarbital may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Pentobarbital.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe metabolism of Fesoterodine can be increased when combined with Pentobarbital.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fexofenadine.Approved
FimasartanPentobarbital may increase the hypotensive activities of Fimasartan.Approved
FinasterideThe metabolism of Finasteride can be increased when combined with Pentobarbital.Approved
FingolimodThe metabolism of Fingolimod can be increased when combined with Pentobarbital.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Pentobarbital.Approved
fluasteroneThe serum concentration of fluasterone can be decreased when it is combined with Pentobarbital.Investigational
FluconazoleThe metabolism of Pentobarbital can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fludiazepam.Approved, Illicit
FludrocortisoneThe serum concentration of Fludrocortisone can be decreased when it is combined with Pentobarbital.Approved
FluindioneThe metabolism of Fluindione can be increased when combined with Pentobarbital.Investigational
FlumethasoneThe serum concentration of Flumethasone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
FlunarizineThe metabolism of Flunarizine can be increased when combined with Pentobarbital.Approved
FlunisolideThe metabolism of Flunisolide can be increased when combined with Pentobarbital.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be increased when combined with Pentobarbital.Approved, Illicit
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be decreased when it is combined with Pentobarbital.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be decreased when it is combined with Pentobarbital.Approved, Withdrawn
FluorometholoneThe metabolism of Fluorometholone can be increased when combined with Pentobarbital.Approved
FluorouracilThe metabolism of Fluorouracil can be increased when combined with Pentobarbital.Approved
FluoxetineThe metabolism of Fluoxetine can be increased when combined with Pentobarbital.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fluphenazine.Approved
FluprednideneThe serum concentration of Fluprednidene can be decreased when it is combined with Pentobarbital.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be decreased when it is combined with Pentobarbital.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be decreased when it is combined with Pentobarbital.Approved
FlurazepamThe metabolism of Flurazepam can be increased when combined with Pentobarbital.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fluspirilene.Approved
FlutamideThe metabolism of Flutamide can be increased when combined with Pentobarbital.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be increased when combined with Pentobarbital.Approved
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be increased when combined with Pentobarbital.Approved
FluvastatinThe metabolism of Fluvastatin can be increased when combined with Pentobarbital.Approved
FluvoxamineThe metabolism of Pentobarbital can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe serum concentration of Formestane can be decreased when it is combined with Pentobarbital.Approved, Investigational, Withdrawn
FormoterolThe metabolism of Formoterol can be increased when combined with Pentobarbital.Approved, Investigational
FosamprenavirThe metabolism of Fosamprenavir can be increased when combined with Pentobarbital.Approved
FosinoprilPentobarbital may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe metabolism of Pentobarbital can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fospropofol.Approved, Illicit
FulvestrantThe metabolism of Fulvestrant can be increased when combined with Pentobarbital.Approved, Investigational
FurosemidePentobarbital may increase the hypotensive activities of Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Pentobarbital is combined with gabapentin enacarbil.Approved
GalantamineThe metabolism of Galantamine can be increased when combined with Pentobarbital.Approved
GallopamilThe metabolism of Gallopamil can be increased when combined with Pentobarbital.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Pentobarbital.Approved, Investigational
GemfibrozilThe metabolism of Gemfibrozil can be increased when combined with Pentobarbital.Approved
GepironeThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Gepirone.Investigational
GestodeneThe therapeutic efficacy of Gestodene can be decreased when used in combination with Pentobarbital.Approved
GlipizideThe metabolism of Glipizide can be increased when combined with Pentobarbital.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Glutethimide.Approved, Illicit
GlyburideThe metabolism of Glyburide can be increased when combined with Pentobarbital.Approved
GranisetronThe metabolism of Granisetron can be increased when combined with Pentobarbital.Approved, Investigational
GrepafloxacinThe metabolism of Grepafloxacin can be increased when combined with Pentobarbital.Withdrawn
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Pentobarbital.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be increased when combined with Pentobarbital.Approved
HaloperidolThe metabolism of Haloperidol can be increased when combined with Pentobarbital.Approved
HalothaneThe metabolism of Halothane can be increased when combined with Pentobarbital.Approved, Vet Approved
HE3286The serum concentration of HE3286 can be decreased when it is combined with Pentobarbital.Investigational
HeroinThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Heroin.Approved, Illicit
HexestrolThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Pentobarbital.Withdrawn
HexobarbitalThe metabolism of Hexobarbital can be increased when combined with Pentobarbital.Approved
Histamine PhosphateThe metabolism of Histamine Phosphate can be increased when combined with Pentobarbital.Approved
HydralazinePentobarbital may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazidePentobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodonePentobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be increased when combined with Pentobarbital.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
HydroflumethiazidePentobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be increased when combined with Pentobarbital.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be increased when combined with Pentobarbital.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Pentobarbital.Approved
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Pentobarbital.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be increased when Ifosfamide is used in combination with Pentobarbital.Approved
IloperidoneThe metabolism of Iloperidone can be increased when combined with Pentobarbital.Approved
IloprostPentobarbital may increase the hypotensive activities of Iloprost.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Pentobarbital.Approved
ImidaprilPentobarbital may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be increased when combined with Pentobarbital.Approved
ImiquimodThe metabolism of Imiquimod can be increased when combined with Pentobarbital.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be increased when combined with Pentobarbital.Approved
IndalpineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Indalpine.Investigational, Withdrawn
IndapamideThe metabolism of Indapamide can be increased when combined with Pentobarbital.Approved
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Pentobarbital.Withdrawn
IndinavirThe metabolism of Indinavir can be increased when combined with Pentobarbital.Approved
IndoraminPentobarbital may increase the hypotensive activities of Indoramin.Withdrawn
Ipratropium bromideThe metabolism of Ipratropium bromide can be increased when combined with Pentobarbital.Approved
IrbesartanPentobarbital may increase the hypotensive activities of Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be reduced when Irinotecan is used in combination with Pentobarbital resulting in a loss in efficacy.Approved, Investigational
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with Pentobarbital resulting in a loss in efficacy.Approved, Investigational
IsocarboxazidPentobarbital may increase the hypotensive activities of Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Pentobarbital can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be increased when combined with Pentobarbital.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be increased when combined with Pentobarbital.Approved
IsoxsuprinePentobarbital may increase the hypotensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Isradipine can be increased when combined with Pentobarbital.Approved
IstaroximeThe serum concentration of Istaroxime can be decreased when it is combined with Pentobarbital.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Pentobarbital.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Pentobarbital.Approved
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Pentobarbital.Approved
IvermectinThe metabolism of Ivermectin can be increased when combined with Pentobarbital.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Pentobarbital.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Pentobarbital.Approved
KetamineThe metabolism of Ketamine can be increased when combined with Pentobarbital.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be increased when combined with Pentobarbital.Approved
KetobemidoneThe metabolism of Ketobemidone can be increased when combined with Pentobarbital.Approved
KetoconazoleThe metabolism of Ketoconazole can be increased when combined with Pentobarbital.Approved, Investigational
LabetalolPentobarbital may increase the hypotensive activities of Labetalol.Approved
LacidipineThe metabolism of Lacidipine can be increased when combined with Pentobarbital.Approved
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Pentobarbital.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be increased when combined with Pentobarbital.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Pentobarbital.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be increased when combined with Pentobarbital.Investigational
LenvatinibThe metabolism of Lenvatinib can be increased when combined with Pentobarbital.Approved
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Pentobarbital.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be increased when combined with Pentobarbital.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Levetiracetam.Approved, Investigational
LevobunololPentobarbital may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe metabolism of Levobupivacaine can be increased when combined with Pentobarbital.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Levocabastine.Approved
LevocetirizineThe metabolism of Levocetirizine can be increased when combined with Pentobarbital.Approved
LevodopaThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Levodopa.Approved
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be increased when combined with Pentobarbital.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be increased when combined with Pentobarbital.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be increased when combined with Pentobarbital.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Levorphanol.Approved
LevosimendanPentobarbital may increase the hypotensive activities of Levosimendan.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be increased when combined with Pentobarbital.Approved
LidocaineThe metabolism of Lidocaine can be increased when combined with Pentobarbital.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Pentobarbital.Approved
LisinoprilPentobarbital may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be increased when combined with Pentobarbital.Approved
LithiumThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Lofentanil.Illicit
LofexidinePentobarbital may increase the hypotensive activities of Lofexidine.Approved, Investigational
LomitapideThe metabolism of Lomitapide can be increased when combined with Pentobarbital.Approved
LoperamideThe metabolism of Loperamide can be increased when combined with Pentobarbital.Approved
LopinavirThe metabolism of Lopinavir can be increased when combined with Pentobarbital.Approved
LoratadineThe metabolism of Loratadine can be increased when combined with Pentobarbital.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pentobarbital.Approved
LorcaserinThe metabolism of Lorcaserin can be increased when combined with Pentobarbital.Approved
LosartanThe metabolism of Losartan can be increased when combined with Pentobarbital.Approved
LovastatinThe metabolism of Lovastatin can be increased when combined with Pentobarbital.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Pentobarbital is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Pentobarbital can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Pentobarbital can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Pentobarbital.Approved
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Pentobarbital.Approved
LynestrenolThe therapeutic efficacy of Lynestrenol can be decreased when used in combination with Pentobarbital.Investigational
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Pentobarbital.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved, Vet Approved
ManidipineThe metabolism of Manidipine can be increased when combined with Pentobarbital.Approved
MannitolPentobarbital may increase the hypotensive activities of Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Maprotiline.Approved
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Pentobarbital.Approved, Investigational
ME-609The serum concentration of ME-609 can be decreased when it is combined with Pentobarbital.Investigational
MebendazoleThe metabolism of Mebendazole can be increased when combined with Pentobarbital.Approved, Vet Approved
MecamylaminePentobarbital may increase the hypotensive activities of Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Medetomidine.Vet Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be increased when combined with Pentobarbital.Approved, Investigational
MedrysoneThe serum concentration of Medrysone can be decreased when it is combined with Pentobarbital.Approved
MefloquineThe metabolism of Mefloquine can be increased when combined with Pentobarbital.Approved
MelatoninThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelengestrolThe serum concentration of Melengestrol can be decreased when it is combined with Pentobarbital.Vet Approved
MeloxicamThe metabolism of Meloxicam can be increased when combined with Pentobarbital.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Meprobamate.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Mesoridazine.Approved
MestranolThe therapeutic efficacy of Mestranol can be decreased when used in combination with Pentobarbital.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Metaxalone.Approved
MethadoneThe metabolism of Methadone can be increased when combined with Pentobarbital.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methadyl Acetate.Approved, Illicit
MethallenestrilThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Pentobarbital.Experimental
MethapyrileneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methapyrilene.Withdrawn
MethaqualoneThe metabolism of Methaqualone can be increased when combined with Pentobarbital.Illicit, Withdrawn
MethazolamidePentobarbital may increase the hypotensive activities of Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methohexital.Approved
MethotrimeprazinePentobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxsalenThe metabolism of Methoxsalen can be increased when combined with Pentobarbital.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be increased when combined with Pentobarbital.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methsuximide.Approved
MethyclothiazidePentobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
MethyldopaPentobarbital may increase the hypotensive activities of Methyldopa.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be increased when combined with Pentobarbital.Approved
MetipranololPentobarbital may increase the hypotensive activities of Metipranolol.Approved
MetolazonePentobarbital may increase the orthostatic hypotensive activities of Metolazone.Approved
MetoprololPentobarbital may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be increased when combined with Pentobarbital.Approved
MetyrosinePentobarbital may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Mexiletine can be increased when combined with Pentobarbital.Approved
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved
MibefradilThe metabolism of Mibefradil can be increased when combined with Pentobarbital.Withdrawn
MiconazoleThe metabolism of Miconazole can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be increased when combined with Pentobarbital.Approved, Illicit
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Pentobarbital.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved, Investigational
MinoxidilPentobarbital may increase the hypotensive activities of Minoxidil.Approved
MirabegronThe metabolism of Mirabegron can be increased when combined with Pentobarbital.Approved
MirtazapinePentobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoclobemideThe metabolism of Pentobarbital can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Modafinil can be increased when combined with Pentobarbital.Approved, Investigational
MoexiprilPentobarbital may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Molindone.Approved
MometasoneThe serum concentration of Mometasone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
MontelukastThe metabolism of Montelukast can be increased when combined with Pentobarbital.Approved
MorphineThe metabolism of Morphine can be increased when combined with Pentobarbital.Approved, Investigational
MoxonidinePentobarbital may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be increased when combined with Pentobarbital.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved, Investigational
NadololPentobarbital may increase the hypotensive activities of Nadolol.Approved
NaftopidilThe metabolism of Naftopidil can be increased when combined with Pentobarbital.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Pentobarbital.Approved
NaloxoneThe metabolism of Naloxone can be increased when combined with Pentobarbital.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be increased when combined with Pentobarbital.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be decreased when it is combined with Pentobarbital.Investigational
NebivololPentobarbital may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Nefazodone can be increased when combined with Pentobarbital.Approved, Withdrawn
NelfinavirThe metabolism of Nelfinavir can be increased when combined with Pentobarbital.Approved
NesiritidePentobarbital may increase the hypotensive activities of Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Netupitant can be decreased when it is combined with Pentobarbital.Approved
NevirapineThe metabolism of Nevirapine can be increased when combined with Pentobarbital.Approved
NicardipineThe metabolism of Nicardipine can be increased when combined with Pentobarbital.Approved
NicotineThe metabolism of Nicotine can be increased when combined with Pentobarbital.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Pentobarbital.Approved
NiguldipineThe metabolism of Niguldipine can be increased when combined with Pentobarbital.Experimental
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Pentobarbital.Approved, Investigational
NiludipineThe metabolism of Niludipine can be increased when combined with Pentobarbital.Experimental
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Pentobarbital.Approved
NimesulideThe metabolism of Nimesulide can be increased when combined with Pentobarbital.Approved, Withdrawn
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Pentobarbital.Approved
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Pentobarbital.Approved
NitrazepamThe metabolism of Nitrazepam can be increased when combined with Pentobarbital.Approved
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Pentobarbital.Approved
Nitric OxidePentobarbital may increase the hypotensive activities of Nitric Oxide.Approved
NitroglycerinPentobarbital may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
NitroprussidePentobarbital may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Nitrous oxide.Approved, Vet Approved
NorelgestrominThe therapeutic efficacy of Norelgestromin can be decreased when used in combination with Pentobarbital.Approved
NorethisteroneThe metabolism of Norethisterone can be increased when combined with Pentobarbital.Approved
NorgestimateThe therapeutic efficacy of Norgestimate can be decreased when used in combination with Pentobarbital.Approved
NorgestrelThe metabolism of Norgestrel can be increased when combined with Pentobarbital.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Normethadone.Approved, Illicit
NortriptylineThe metabolism of Nortriptyline can be increased when combined with Pentobarbital.Approved
ObinutuzumabPentobarbital may increase the hypotensive activities of Obinutuzumab.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Pentobarbital.Approved
Oleoyl estroneThe serum concentration of Oleoyl estrone can be decreased when it is combined with Pentobarbital.Investigational
OlmesartanPentobarbital may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlopatadineThe metabolism of Olopatadine can be increased when combined with Pentobarbital.Approved
OmeprazoleThe metabolism of Omeprazole can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be increased when combined with Pentobarbital.Approved
OpipramolThe metabolism of Opipramol can be increased when combined with Pentobarbital.Investigational
OpiumThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Opium.Approved, Illicit
OrphenadrinePentobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Pentobarbital.Approved
OspemifeneThe metabolism of Ospemifene can be increased when combined with Pentobarbital.Approved
OxazepamThe metabolism of Oxazepam can be increased when combined with Pentobarbital.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Oxybuprocaine.Approved
OxybutyninThe metabolism of Oxybutynin can be increased when combined with Pentobarbital.Approved, Investigational
OxycodoneThe metabolism of Oxycodone can be increased when combined with Pentobarbital.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be increased when combined with Pentobarbital.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Pentobarbital.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be increased when combined with Pentobarbital.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Pentobarbital.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be increased when combined with Pentobarbital.Approved
PapaverinePentobarbital may increase the hypotensive activities of Papaverine.Approved
ParaldehydePentobarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParamethadioneThe metabolism of Paramethadione can be increased when combined with Pentobarbital.Approved
ParamethasoneThe metabolism of Paramethasone can be increased when combined with Pentobarbital.Approved
ParecoxibThe metabolism of Parecoxib can be increased when combined with Pentobarbital.Approved
ParicalcitolThe metabolism of Paricalcitol can be increased when combined with Pentobarbital.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be increased when combined with Pentobarbital.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Pentobarbital.Approved
PenbutololPentobarbital may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineThe metabolism of Pentamidine can be increased when combined with Pentobarbital.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pentazocine.Approved, Vet Approved
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Pentobarbital.Approved
PerazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Perazine.Investigational
PergolideThe metabolism of Pergolide can be increased when combined with Pentobarbital.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be increased when combined with Pentobarbital.Approved
PerindoprilPentobarbital may increase the hypotensive activities of Perindopril.Approved
PermethrinThe metabolism of Permethrin can be increased when combined with Pentobarbital.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be increased when combined with Pentobarbital.Approved
PethidinePentobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenacetinThe metabolism of Phenacetin can be increased when combined with Pentobarbital.Withdrawn
PhenelzinePentobarbital may increase the hypotensive activities of Phenelzine.Approved
PhenindioneThe metabolism of Phenindione can be increased when combined with Pentobarbital.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be increased when combined with Pentobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Phenoxyethanol.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Pentobarbital.Approved
PhentolaminePentobarbital may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe metabolism of Phenytoin can be increased when combined with Pentobarbital.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be increased when combined with Pentobarbital.Approved
PimecrolimusThe metabolism of Pimecrolimus can be increased when combined with Pentobarbital.Approved, Investigational
PimozideThe metabolism of Pimozide can be increased when combined with Pentobarbital.Approved
PinacidilThe metabolism of Pinacidil can be increased when combined with Pentobarbital.Withdrawn
PinaveriumThe metabolism of Pinaverium can be increased when combined with Pentobarbital.Approved
PindololPentobarbital may increase the hypotensive activities of Pindolol.Approved
PioglitazoneThe metabolism of Pioglitazone can be increased when combined with Pentobarbital.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pipamperone.Approved
PipotiazineThe metabolism of Pipotiazine can be increased when combined with Pentobarbital.Approved
PiritramideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pizotifen.Approved
PodofiloxThe metabolism of Podofilox can be increased when combined with Pentobarbital.Approved
PolythiazidePentobarbital may increase the orthostatic hypotensive activities of Polythiazide.Approved
PomalidomideThe metabolism of Pomalidomide can be increased when combined with Pentobarbital.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Pentobarbital.Approved
PosaconazoleThe metabolism of Posaconazole can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PractololThe serum concentration of Practolol can be decreased when it is combined with Pentobarbital.Approved
PramipexolePentobarbital may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pramocaine.Approved
PrasteroneThe metabolism of Prasterone can be increased when combined with Pentobarbital.Approved, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be increased when combined with Pentobarbital.Approved
PravastatinThe metabolism of Pravastatin can be increased when combined with Pentobarbital.Approved
PrazepamThe metabolism of Prazepam can be increased when combined with Pentobarbital.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PrazosinPentobarbital may increase the hypotensive activities of Prazosin.Approved
PrednicarbateThe serum concentration of Prednicarbate can be decreased when it is combined with Pentobarbital.Approved
PrednisoloneThe metabolism of Prednisolone can be increased when combined with Pentobarbital.Approved, Vet Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pentobarbital.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pregnanolone.Investigational
PregnenoloneThe serum concentration of Pregnenolone can be decreased when it is combined with Pentobarbital.Experimental
PrenylamineThe metabolism of Prenylamine can be increased when combined with Pentobarbital.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Prilocaine.Approved
PrimaquineThe metabolism of Primaquine can be increased when combined with Pentobarbital.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Pentobarbital.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe metabolism of Prochlorperazine can be increased when combined with Pentobarbital.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be increased when combined with Pentobarbital.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be increased when combined with Pentobarbital.Approved
PromazineThe metabolism of Promazine can be increased when combined with Pentobarbital.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Promethazine.Approved
PropacetamolThe metabolism of Propacetamol can be increased when combined with Pentobarbital.Approved
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Pentobarbital.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Proparacaine.Approved, Vet Approved
PropofolThe metabolism of Propofol can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Propoxycaine.Approved
PropranololThe metabolism of Propranolol can be increased when combined with Pentobarbital.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be increased when combined with Pentobarbital.Approved
PSD502The risk or severity of adverse effects can be increased when Pentobarbital is combined with PSD502.Investigational
PyrazinamideThe metabolism of Pyrazinamide can be increased when combined with Pentobarbital.Approved
PyridoxineThe metabolism of Pentobarbital can be increased when combined with Pyridoxine.Approved, Nutraceutical, Vet Approved
QuazepamThe metabolism of Quazepam can be increased when combined with Pentobarbital.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Pentobarbital.Approved
QuinacrineThe metabolism of Quinacrine can be increased when combined with Pentobarbital.Approved
QuinaprilPentobarbital may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazonePentobarbital may increase the orthostatic hypotensive activities of Quinethazone.Approved
QuinidineThe metabolism of Quinidine can be increased when combined with Pentobarbital.Approved
QuinineThe metabolism of Quinine can be increased when combined with Pentobarbital.Approved
RabeprazoleThe metabolism of Rabeprazole can be increased when combined with Pentobarbital.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Raclopride.Investigational
RaloxifeneThe metabolism of Raloxifene can be increased when combined with Pentobarbital.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be increased when combined with Pentobarbital.Approved, Investigational
RamiprilPentobarbital may increase the hypotensive activities of Ramipril.Approved
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Pentobarbital.Approved, Investigational
RasagilinePentobarbital may increase the hypotensive activities of Rasagiline.Approved
ReboxetineThe metabolism of Reboxetine can be increased when combined with Pentobarbital.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Pentobarbital.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe metabolism of Repaglinide can be increased when combined with Pentobarbital.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pentobarbital.Approved
RetapamulinThe metabolism of Retapamulin can be increased when combined with Pentobarbital.Approved
RifabutinThe metabolism of Rifabutin can be increased when combined with Pentobarbital.Approved
RifampicinThe metabolism of Rifampicin can be increased when combined with Pentobarbital.Approved
RifapentineThe metabolism of Pentobarbital can be increased when combined with Rifapentine.Approved
RilpivirineThe metabolism of Rilpivirine can be increased when combined with Pentobarbital.Approved
RimexoloneThe serum concentration of Rimexolone can be decreased when it is combined with Pentobarbital.Approved
RimonabantThe metabolism of Rimonabant can be increased when combined with Pentobarbital.Approved, Investigational
RiociguatThe metabolism of Riociguat can be increased when combined with Pentobarbital.Approved
RisedronateThe metabolism of Risedronate can be increased when combined with Pentobarbital.Approved, Investigational
RisperidoneThe metabolism of Risperidone can be increased when combined with Pentobarbital.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ritanserin.Investigational
RitonavirThe metabolism of Ritonavir can be increased when combined with Pentobarbital.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Pentobarbital.Approved
RofecoxibThe metabolism of Rofecoxib can be increased when combined with Pentobarbital.Investigational, Withdrawn
RoflumilastThe serum concentration of Roflumilast can be decreased when it is combined with Pentobarbital.Approved
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Pentobarbital.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Pentobarbital.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Romifidine.Vet Approved
RopinirolePentobarbital may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be increased when combined with Pentobarbital.Approved
RosuvastatinThe metabolism of Rosuvastatin can be increased when combined with Pentobarbital.Approved
RotigotinePentobarbital may increase the sedative activities of Rotigotine.Approved
RoxithromycinThe metabolism of Roxithromycin can be increased when combined with Pentobarbital.Approved, Withdrawn
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pentobarbital.Approved
RuxolitinibThe metabolism of Ruxolitinib can be increased when combined with Pentobarbital.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Pentobarbital is combined with S-Ethylisothiourea.Experimental
SacubitrilPentobarbital may increase the hypotensive activities of Sacubitril.Approved
Sage 547The risk or severity of adverse effects can be increased when Pentobarbital is combined with Sage 547.Investigational
SalmeterolThe metabolism of Salmeterol can be increased when combined with Pentobarbital.Approved
SaquinavirThe metabolism of Saquinavir can be increased when combined with Pentobarbital.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Pentobarbital.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be increased when combined with Pentobarbital.Approved
SeratrodastThe metabolism of Seratrodast can be increased when combined with Pentobarbital.Approved, Investigational
SertindoleThe metabolism of Sertindole can be increased when combined with Pentobarbital.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be increased when combined with Pentobarbital.Approved
SevofluraneThe metabolism of Sevoflurane can be increased when combined with Pentobarbital.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be increased when combined with Pentobarbital.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Sildenafil can be increased when combined with Pentobarbital.Approved, Investigational
SilodosinThe metabolism of Silodosin can be increased when combined with Pentobarbital.Approved
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Pentobarbital.Approved
SimvastatinThe metabolism of Simvastatin can be increased when combined with Pentobarbital.Approved
SirolimusThe metabolism of Sirolimus can be increased when combined with Pentobarbital.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be increased when combined with Pentobarbital.Approved, Investigational
Sodium NitritePentobarbital may increase the hypotensive activities of Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved
SolifenacinThe metabolism of Solifenacin can be increased when combined with Pentobarbital.Approved
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Pentobarbital.Approved
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Pentobarbital.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Pentobarbital.Approved, Investigational
SotalolPentobarbital may increase the hypotensive activities of Sotalol.Approved
SpiramycinThe metabolism of Spiramycin can be increased when combined with Pentobarbital.Approved
SpironolactonePentobarbital may increase the hypotensive activities of Spironolactone.Approved
StiripentolThe metabolism of Pentobarbital can be decreased when combined with Stiripentol.Approved
StreptokinasePentobarbital may increase the hypotensive activities of Streptokinase.Approved
SufentanilThe metabolism of Sufentanil can be increased when combined with Pentobarbital.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be increased when combined with Pentobarbital.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be increased when combined with Pentobarbital.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be increased when combined with Pentobarbital.Approved
SulpirideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Sulpiride.Approved
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Pentobarbital.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be decreased when it is combined with Pentobarbital.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be increased when combined with Pentobarbital.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Pentobarbital.Approved
TacrolimusThe metabolism of Tacrolimus can be increased when combined with Pentobarbital.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Pentobarbital.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be increased when combined with Pentobarbital.Approved
TamsulosinThe metabolism of Tamsulosin can be increased when combined with Pentobarbital.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved
TasimelteonThe serum concentration of Tasimelteon can be decreased when it is combined with Pentobarbital.Approved
TasosartanThe metabolism of Tasosartan can be increased when combined with Pentobarbital.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be increased when combined with Pentobarbital.Experimental
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Pentobarbital.Approved
TelithromycinThe metabolism of Telithromycin can be increased when combined with Pentobarbital.Approved
TelmisartanPentobarbital may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be increased when combined with Pentobarbital.Approved
TemsirolimusThe metabolism of Temsirolimus can be increased when combined with Pentobarbital.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Pentobarbital.Approved
TerazosinPentobarbital may increase the hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be increased when combined with Pentobarbital.Withdrawn
TesmilifeneThe metabolism of Tesmilifene can be increased when combined with Pentobarbital.Investigational
TestosteroneThe metabolism of Testosterone can be increased when combined with Pentobarbital.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tetracaine.Approved, Vet Approved
TetracyclineThe metabolism of Tetracycline can be increased when combined with Pentobarbital.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tetrodotoxin.Investigational
ThalidomidePentobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be increased when combined with Pentobarbital.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Thioridazine.Approved
ThiotepaThe metabolism of Thiotepa can be increased when combined with Pentobarbital.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Thiothixene.Approved
TiagabineThe metabolism of Tiagabine can be increased when combined with Pentobarbital.Approved
TianeptineThe metabolism of Tianeptine can be increased when combined with Pentobarbital.Approved
TiaprideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tiapride.Investigational
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Pentobarbital resulting in a loss in efficacy.Approved
TiclopidineThe metabolism of Ticlopidine can be increased when combined with Pentobarbital.Approved
TiletamineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tiletamine.Vet Approved
TimololPentobarbital may increase the hypotensive activities of Timolol.Approved
TinidazoleThe metabolism of Tinidazole can be increased when combined with Pentobarbital.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be increased when combined with Pentobarbital.Approved
TipranavirThe metabolism of Tipranavir can be increased when combined with Pentobarbital.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be decreased when it is combined with Pentobarbital.Approved
TizanidineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tizanidine.Approved
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Pentobarbital.Approved, Investigational
TolazolinePentobarbital may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Pentobarbital.Approved
TolterodineThe metabolism of Tolterodine can be increased when combined with Pentobarbital.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Pentobarbital.Approved
TopiramateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Topiramate.Approved
TorasemidePentobarbital may increase the hypotensive activities of Torasemide.Approved
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Pentobarbital.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Pentobarbital.Approved, Investigational
TramadolThe metabolism of Tramadol can be increased when combined with Pentobarbital.Approved, Investigational
TrandolaprilPentobarbital may increase the hypotensive activities of Trandolapril.Approved
TranilastThe metabolism of Tranilast can be increased when combined with Pentobarbital.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tranylcypromine.Approved
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be increased when combined with Pentobarbital.Approved
TrazodoneThe metabolism of Trazodone can be increased when combined with Pentobarbital.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be increased when combined with Pentobarbital.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be increased when combined with Pentobarbital.Approved, Vet Approved
TriamterenePentobarbital may increase the hypotensive activities of Triamterene.Approved
TriazolamThe metabolism of Triazolam can be increased when combined with Pentobarbital.Approved
TrichlormethiazidePentobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be increased when combined with Pentobarbital.Approved
TrimethoprimThe metabolism of Trimethoprim can be increased when combined with Pentobarbital.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be increased when combined with Pentobarbital.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Triprolidine.Approved
TroglitazoneThe metabolism of Troglitazone can be increased when combined with Pentobarbital.Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be increased when combined with Pentobarbital.Approved
Uc1010The risk or severity of adverse effects can be increased when Pentobarbital is combined with Uc1010.Investigational
UdenafilThe metabolism of Udenafil can be increased when combined with Pentobarbital.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Pentobarbital.Approved
ValdecoxibThe metabolism of Valdecoxib can be increased when combined with Pentobarbital.Investigational, Withdrawn
Valproic AcidThe serum concentration of Pentobarbital can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanPentobarbital may increase the hypotensive activities of Valsartan.Approved, Investigational
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Pentobarbital.Approved
VanoxerineThe metabolism of Vanoxerine can be increased when combined with Pentobarbital.Investigational
VardenafilThe metabolism of Vardenafil can be increased when combined with Pentobarbital.Approved
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Pentobarbital.Approved
VenetoclaxThe metabolism of Venetoclax can be increased when combined with Pentobarbital.Approved
VenlafaxineThe metabolism of Venlafaxine can be increased when combined with Pentobarbital.Approved
VerapamilThe metabolism of Verapamil can be increased when combined with Pentobarbital.Approved
VicrivirocThe metabolism of Vicriviroc can be increased when combined with Pentobarbital.Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Vigabatrin.Approved
VilanterolThe metabolism of Vilanterol can be increased when combined with Pentobarbital.Approved
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Pentobarbital.Approved
VinblastineThe metabolism of Vinblastine can be increased when combined with Pentobarbital.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Pentobarbital.Approved, Investigational
VincristineThe metabolism of Vincristine can be increased when combined with Pentobarbital.Approved, Investigational
VindesineThe metabolism of Vindesine can be increased when combined with Pentobarbital.Approved
VinorelbineThe metabolism of Vinorelbine can be increased when combined with Pentobarbital.Approved, Investigational
VinpocetineThe metabolism of Vinpocetine can be increased when combined with Pentobarbital.Investigational
VismodegibThe metabolism of Vismodegib can be increased when combined with Pentobarbital.Approved
VorapaxarThe serum concentration of Vorapaxar can be decreased when it is combined with Pentobarbital.Approved
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Pentobarbital.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Pentobarbital.Approved
WarfarinThe metabolism of Warfarin can be increased when combined with Pentobarbital.Approved
XylazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Xylazine.Vet Approved
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Pentobarbital.Approved
YohimbineThe metabolism of Yohimbine can be increased when combined with Pentobarbital.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be increased when combined with Pentobarbital.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be increased when combined with Pentobarbital.Approved
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Pentobarbital.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ziconotide.Approved
ZidovudineThe metabolism of Zidovudine can be increased when combined with Pentobarbital.Approved
ZileutonThe metabolism of Zileuton can be increased when combined with Pentobarbital.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be increased when combined with Pentobarbital.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Zolazepam.Vet Approved
ZolpidemPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracThe metabolism of Zomepirac can be increased when combined with Pentobarbital.Withdrawn
ZonisamideThe metabolism of Zonisamide can be increased when combined with Pentobarbital.Approved, Investigational
ZopicloneThe metabolism of Zopiclone can be increased when combined with Pentobarbital.Approved
ZotepineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Zotepine.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be decreased when it is combined with Pentobarbital.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Knodell RG, Spector MH, Brooks DA, Keller FX, Kyner WT: Alterations in pentobarbital pharmacokinetics in response to parenteral and enteral alimentation in the rat. Gastroenterology. 1980 Dec;79(6):1211-6. [PubMed:6777235 ]
External Links
ATC CodesN05CA01
AHFS Codes
  • 28:24.04
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (50.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier+0.9713
Caco-2 permeable-0.5926
P-glycoprotein substrateSubstrate0.5947
P-glycoprotein inhibitor INon-inhibitor0.6155
P-glycoprotein inhibitor IINon-inhibitor0.9218
Renal organic cation transporterNon-inhibitor0.923
CYP450 2C9 substrateNon-substrate0.7789
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.7066
CYP450 1A2 substrateNon-inhibitor0.9086
CYP450 2C9 inhibitorNon-inhibitor0.7484
CYP450 2D6 inhibitorNon-inhibitor0.9301
CYP450 2C19 inhibitorNon-inhibitor0.711
CYP450 3A4 inhibitorNon-inhibitor0.9522
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9276
Ames testNon AMES toxic0.6789
CarcinogenicityNon-carcinogens0.89
BiodegradationNot ready biodegradable0.9603
Rat acute toxicity3.2266 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9685
hERG inhibition (predictor II)Non-inhibitor0.8771
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ovation pharmaceuticals inc
  • Lannett co inc
  • Vitarine pharmaceuticals inc
  • Whiteworth towne paulsen inc
  • Anabolic inc
  • Elkins sinn div ah robins co inc
  • Everylife
  • Halsey drug co inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Parke davis div warner lambert co
  • L perrigo co
  • Purepac pharmaceutical co
  • Valeant pharmaceuticals international
  • Watson laboratories inc
  • Wyeth ayerst laboratories
  • Lundbeck inc
  • Nexgen pharma inc
Packagers
Dosage forms
FormRouteStrength
InjectionIntramuscular; Intravenous50 mg/mL
CapsuleOral100 mg
SolutionIntramuscular; Intravenous50 mg
SuppositoryRectal25 mg
SuppositoryRectal50 mg
CapsuleOral50 mg
Prices
Unit descriptionCostUnit
Pentobarbital sodium powder27.0USD g
Nembutal sodium 50 mg/ml via20.65USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point129.5 °CPhysProp
water solubility679 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.10HANSCH,C ET AL. (1995)
logS-2.52ADME Research, USCD
pKa8.11 (at 25 °C)SERJEANT,EP & DEMPSEY,B (1979)
Predicted Properties
PropertyValueSource
Water Solubility0.864 mg/mLALOGPS
logP2.16ALOGPS
logP1.89ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)8.48ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity58 m3·mol-1ChemAxon
Polarizability23.41 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.77 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-004i-1290000000-90bfbd79bea4fe2b007bView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-0bti-1900000000-7e31dcdb272669c13101View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-01bc-9100000000-c9fe8276b8137dc73d20View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-004i-3980000000-84ea889a0fae4bed224bView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-0006-9500000000-c226fe2dfb4ee13e4ae8View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-000x-9500000000-cd4190b9c110ee5e4428View in MoNA
MSMass Spectrum (Electron Ionization)splash10-0a4l-6900000000-a65d8c67e006ad448814View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentBarbituric acid derivatives
Alternative Parents
Substituents
  • Barbiturate
  • Ureide
  • 1,3-diazinane
  • Urea
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Steinbach JH, Akk G: Modulation of GABA(A) receptor channel gating by pentobarbital. J Physiol. 2001 Dec 15;537(Pt 3):715-33. [PubMed:11744750 ]
  2. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514 ]
  3. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  4. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
  5. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  6. Davies DL, McCauley LD, Bolger MB, Alkana RL: Pressure-sensitive and -insensitive coupling in gamma-aminobutyric acid(A) receptors. Psychopharmacology (Berl). 2001 Oct;157(4):401-10. [PubMed:11605100 ]
  7. Rahman M, Zhu D, Lindblad C, Johansson IM, Holmberg E, Isaksson M, Taube M, Backstrom T, Wang MD: GABA-site antagonism and pentobarbital actions do not depend on the alpha-subunit type in the recombinant rat GABA receptor. Acta Physiol (Oxf). 2006 Aug;187(4):479-88. [PubMed:16866778 ]
  8. Feigenspan A, Weiler R: Electrophysiological properties of mouse horizontal cell GABAA receptors. J Neurophysiol. 2004 Nov;92(5):2789-801. Epub 2004 Jul 7. [PubMed:15240758 ]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  10. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  11. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
Gene Name:
CHRNA4
Uniprot ID:
P43681
Molecular Weight:
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Toxic substance binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
Gene Name:
CHRNA7
Uniprot ID:
P36544
Molecular Weight:
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ionotropic glutamate receptor activity
Specific Function:
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and t...
Gene Name:
GRIA2
Uniprot ID:
P42262
Molecular Weight:
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Kainate selective glutamate receptor activity
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIK2
Uniprot ID:
Q13002
Molecular Weight:
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated cation channel activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (By similarity).
Components:
NameUniProt IDDetails
Glutamate receptor ionotropic, NMDA 1Q05586 Details
Glutamate receptor ionotropic, NMDA 2AQ12879 Details
Glutamate receptor ionotropic, NMDA 2BQ13224 Details
Glutamate receptor ionotropic, NMDA 2CQ14957 Details
Glutamate receptor ionotropic, NMDA 2DO15399 Details
Glutamate receptor ionotropic, NMDA 3AQ8TCU5 Details
Glutamate receptor ionotropic, NMDA 3BO60391 Details
References
  1. Daniell LC: Effect of anesthetic and convulsant barbiturates on N-methyl-D-aspartate receptor-mediated calcium flux in brain membrane vesicles. Pharmacology. 1994 Nov;49(5):296-307. [PubMed:7862741 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23